Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1875
http://purl.obolibrary.org/obo/NCIT_C1875
|
|---|---|
| Preferred Name | Rebimastat |
| Definitions |
A sulfhydryl-based second-generation matrix metalloproteinase (MMP) inhibitor with potential antineoplastic activity. Rebimastat selectively inhibits several MMPs (MMP 1, 2, 8, 9, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A sulfhydryl-based second-generation matrix metalloproteinase (MMP) inhibitor with potential antineoplastic activity. Rebimastat selectively inhibits several MMPs (MMP 1, 2, 8, 9, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. |
|---|---|
| prefLabel | Rebimastat
|
| label | Rebimastat
|
| PDQ_Closed_Trial_Search_ID | 38088
|
| code | C1875
|
| Has_Target | |
| prefixIRI | NCIT:C1875
|
| in_subset |
See more
See less
|
| Display_Name | Rebimastat
|
| Preferred_Name | Rebimastat
|
| FDA_UNII_Code | 1B47R6ZX4K
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C23H41N5O5S
|
| Maps_To | Rebimastat
|
| CAS_Registry | 259188-38-0
|
| NSC Number | 713763
|
| NCI_Drug_Dictionary_ID | 38088
|
| Legacy Concept Name | BMS-275291
|
| type | |
| ALT_DEFINITION | A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called matrix metalloproteinase inhibitors (MMPIs).
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 38088
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C0935902
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |